Aurinia Pharmaceuticals Inc. Operating Income
Aurinia Pharmaceuticals Inc. (AUPH) reported Operating Income of $46.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. operating income (loss) for the quarter ending 2026-06-30 was $46.34M, a 130.75% increase year-over-year.
- Aurinia Pharmaceuticals Inc. operating income (loss) for the quarter ending 2026-03-31 was $41.42M, a 89.60% increase year-over-year.
- Aurinia Pharmaceuticals Inc. operating income (loss) for the quarter ending 2025-12-31 was $33.24M.
- Aurinia Pharmaceuticals Inc. operating income (loss) for the quarter ending 2025-09-30 was $29.75M, a 153.19% increase year-over-year.
- Aurinia Pharmaceuticals Inc. operating income (loss) for fiscal 2025 was $104.91M.
- Aurinia Pharmaceuticals Inc. operating income (loss) for fiscal 2024 was -$4.69M.
- Aurinia Pharmaceuticals Inc. operating income (loss) for fiscal 2023 was -$91.69M.
- Aurinia Pharmaceuticals Inc. operating income (loss) for fiscal 2022 was -$111.47M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $46.34M 10-Q · filed 2026-08-06 | $87.76M 10-Q · filed 2026-08-06 | $121.00M derived: sum of 3 quarters · filed 2026-08-06 | $150.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $41.42M 10-Q · filed 2026-05-07 | $74.66M derived: sum of 2 quarters · filed 2026-05-07 | $104.41M derived: sum of 3 quarters · filed 2026-05-07 | $124.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $33.24M 10-K · filed 2026-02-26 | $62.98M derived: sum of 2 quarters · filed 2026-02-26 | $83.07M derived: sum of 3 quarters · filed 2026-08-06 | $104.91M 10-K · filed 2026-02-26 |
| 2025-09-30 | $29.75M 10-K · filed 2026-02-26 | $49.83M derived: sum of 2 quarters · filed 2026-08-06 | $71.67M 10-Q · filed 2025-11-04 | $70.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $20.08M 10-Q · filed 2026-08-06 | $41.93M 10-Q · filed 2026-08-06 | $40.26M derived: sum of 3 quarters · filed 2026-08-06 | $52.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $21.85M 10-Q · filed 2026-05-07 | $20.18M derived: sum of 2 quarters · filed 2026-05-07 | $31.93M derived: sum of 3 quarters · filed 2026-05-07 | $30.41M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.67M 10-K · filed 2026-02-26 | $10.08M derived: sum of 2 quarters · filed 2026-02-26 | $8.57M derived: sum of 3 quarters · filed 2026-02-26 | -$4.69M 10-K · filed 2026-02-26 |
| 2024-09-30 | $11.75M 10-K · filed 2026-02-26 | $10.23M derived: sum of 2 quarters · filed 2026-02-26 | -$3.02M 10-Q · filed 2025-11-04 | -$32.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$1.51M 10-K · filed 2026-02-26 | -$14.77M 10-Q · filed 2025-07-31 | -$44.44M derived: sum of 3 quarters · filed 2026-02-26 | -$60.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$13.25M 10-K · filed 2026-02-26 | -$42.93M derived: sum of 2 quarters · filed 2026-02-26 | -$59.19M derived: sum of 3 quarters · filed 2026-02-26 | -$75.36M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$29.67M 10-K · filed 2025-02-27 | -$45.94M derived: sum of 2 quarters · filed 2025-02-27 | -$62.11M derived: sum of 3 quarters · filed 2025-02-27 | -$91.69M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$16.26M 10-K · filed 2025-02-27 | -$32.43M derived: sum of 2 quarters · filed 2025-02-27 | -$62.02M 10-Q · filed 2024-11-07 | -$90.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$16.17M 10-K · filed 2025-02-27 | -$45.75M 10-Q · filed 2024-08-01 | -$73.85M derived: sum of 3 quarters · filed 2025-02-27 | -$83.35M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$29.58M 10-K · filed 2025-02-27 | -$57.68M derived: sum of 2 quarters · filed 2025-02-27 | -$67.18M derived: sum of 3 quarters · filed 2025-02-27 | -$103.17M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$28.10M 10-K · filed 2024-02-15 | -$37.60M derived: sum of 2 quarters · filed 2024-02-15 | -$73.59M derived: sum of 3 quarters · filed 2024-02-15 | -$111.47M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$9.50M 10-K · filed 2024-02-15 | -$45.49M derived: sum of 2 quarters · filed 2024-02-15 | -$83.37M 10-Q · filed 2023-11-02 | -$116.08M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$35.99M 10-K · filed 2024-02-15 | -$73.87M 10-Q · filed 2023-08-03 | -$106.58M derived: sum of 3 quarters · filed 2024-02-15 | -$156.93M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$37.88M 10-K · filed 2024-02-15 | -$70.59M derived: sum of 2 quarters · filed 2024-02-15 | -$120.94M derived: sum of 3 quarters · filed 2024-02-15 | -$168.07M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$32.70M 10-K · filed 2023-02-28 | -$83.06M derived: sum of 2 quarters · filed 2023-02-28 | -$130.19M derived: sum of 3 quarters · filed 2023-02-28 | -$180.74M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$50.35M 10-K · filed 2023-02-28 | -$97.49M derived: sum of 2 quarters · filed 2023-02-28 | -$148.03M 10-Q · filed 2022-11-03 | -$156.08M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$47.13M 10-K · filed 2023-02-28 | -$97.68M 10-Q · filed 2022-08-04 | -$105.73M derived: sum of 3 quarters · filed 2023-02-28 | -$148.04M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$50.54M 10-K · filed 2023-02-28 | -$58.59M derived: sum of 2 quarters · filed 2023-02-28 | -$100.91M derived: sum of 3 quarters · filed 2023-02-28 | -$127.77M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$8.05M 10-K · filed 2022-02-28 | -$50.37M derived: sum of 2 quarters · filed 2022-02-28 | -$77.23M derived: sum of 3 quarters · filed 2022-02-28 | -$104.29M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$42.31M 10-K · filed 2022-02-28 | -$69.18M derived: sum of 2 quarters · filed 2022-02-28 | -$96.24M 10-Q · filed 2021-11-03 | -$131.08M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$26.86M 10-K · filed 2022-02-28 | -$53.92M 10-Q · filed 2021-08-05 | -$88.76M derived: sum of 3 quarters · filed 2022-02-28 | -$112.83M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$27.06M 10-K · filed 2022-02-28 | -$61.90M derived: sum of 2 quarters · filed 2022-02-28 | -$85.97M derived: sum of 3 quarters · filed 2022-02-28 | -$103.11M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$34.84M 10-K · filed 2021-02-24 | -$58.91M derived: sum of 2 quarters · filed 2021-02-24 | -$76.05M derived: sum of 3 quarters · filed 2021-02-24 | -$90.94M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$24.07M 10-K · filed 2021-02-24 | -$41.21M derived: sum of 2 quarters · filed 2021-02-24 | -$56.10M derived: sum of 3 quarters · filed 2021-02-24 | |
| 2019-06-30 | -$17.14M 10-K · filed 2021-02-24 | -$32.03M derived: sum of 2 quarters · filed 2021-02-24 | ||
| 2019-03-31 | -$14.89M 10-K · filed 2021-02-24 | |||
| 2018-12-31 | -$55.24M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |